A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer

被引：0

作者：

Reckamp, Karen L. ^{[1
]}

Akerley, Wallace ^{[2
]}

Edelman, Martin J. ^{[3
]}

Halmos, Balazs ^{[4
]}

He, Kai ^{[5
,6
]}

Johnson, Melissa ^{[7
]}

Mudad, Raja ^{[8
,9
]}

Neal, Joel W. ^{[10
]}

Owonikoko, Taofeek K. ^{[11
]}

Patel, Jyoti D. ^{[12
]}

Patel, Sandip P. ^{[13
]}

Riess, Jonathan W. ^{[14
]}

Sacher, Adrian G. ^{[15
]}

Turcotte, Simon ^{[16
]}

Villaruz, Liza C. ^{[17
]}

Zauderer, Marjorie G. ^{[18
]}

Farsaci, Benedetto ^{[19
]}

Hasan, Aisha ^{[19
]}

Patel, Roma ^{[20
]}

Wu, Yuehui ^{[19
]}

Chisamore, Michael ^{[21
]}

Lam, Vincent ^{[22
]}

机构：

[1] City Hope Comprehens Canc Ctr, Duarte, CA USA

[2] Huntsman Canc Inst, Salt Lake City, UT USA

[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[4] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[6] James Canc Hosp, Columbus, OH USA

[7] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[8] Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA

[9] Sylvester Comprehens Canc Ctr, Miami, FL USA

[10] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Univ Chicago, Chicago, IL 60637 USA

[13] UC San Diego Moores Canc Ctr, San Diego, CA USA

[14] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[17] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[18] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[19] GSK, Philadelphia, PA USA

[20] GSK, Uxbridge, Middx, England

[21] Merck & Co Inc, N Wales, PA USA

[22] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT225

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT225

引用

页数：3

共 34 条

[21] Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets.
Mohanram, Venkat
Belkina, Natalya
Bisconte, Angelina R.
Goldman, Jonathan W.
Gerstner, Gregory J.
Haigentz, Missak
Stinchcombe, Thomas
Halmos, Balazs
Vangala, Surya
Kabala, Victor
Simkhada, Dinesh
Metran, Cristiane
Davis, Darren
Parsi, Megan
Gutierrez, Andres A.
Phippard, Deborah
Ramalingam, Suresh S.
CANCER RESEARCH, 2021, 81 (13)
[22] A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer.
Pinder, Mary Colleen
Rizvi, Naiyer A.
Goldberg, Sarah B.
Balmanoukian, Ani Sarkis
Narwal, Ralesh
Robbins, Paul B.
D'Angelo, Gina
Blake-Haskins, Andy
Karakunnel, Joyson Joseph
Antonia, Scott Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[23] Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study
He, Jing
Ma, Pei
Zhao, Dongmei
Shi, Xinsheng
Guo, Renhua
Gao, Wen
Shu, Yongqian
CANCER, 2023, 129 (10) : 1513 - 1522
[24] Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
Veluswamy, Rajwanth
Bhalla, Sheena
Mehra, Ranee
Garassino, Marina Chiara
Gligich, Oleg
Oliva, Cristina
Gorcea-Carson, Claudia
McCracken, Nigel William
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors
Negrao, Marcelo Vailati
Morelli, Maria Pia
Jazaeri, Amir A.
Johnson, Benny
Kebriaei, Partow
Deninger, Drew
De Groot, Eleanor
Collinson-Pautz, Matthew R.
Demars, Nathan A.
Holland, Jaymes S.
Heymach, John
Baffa, Raffaele
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] A phase II study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Lee, Sylvia
Villaflor, Viktoriya
Haigentz, Missack
Karyampudi, Kumar
Tanamly, Susie
Suzuki, Sam
Gorbatchevsky, Igor
Fardis, Maria
Villaruz, Liza
CANCER RESEARCH, 2018, 78 (13)
[27] Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).
Spigel, David R.
Shum, Merrill Kingman
Schneider, Jeffrey Gary
Jotte, Robert M.
Eisenstein, Jennifer L.
Bhanderi, Viralkumar K.
Konduri, Kartik
Hung, Annie
Hozak, Rebecca R.
Ferry, David Raymond
Gandhi, Leena
Chao, Bo H.
Rybkin, Igor I.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naive patients with advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
Mok, Tony S. K.
Luigi Cortinovis, Diego
Majem, Margarita
Lynne Johnson, Melissa
Ingriani Mardjuadi, Feby
Zhao, Xuan
Vidya Siripurapu, Sagar
Jiang, Zhiqiang
Wolf, Juergen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[29] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
M. Thomas
P. Sadjadian
J. Kollmeier
J. Lowe
P. Mattson
J. R. Trout
M. Gargano
M. L. Patchen
R. Walsh
M. Beliveau
J. F. Marier
N. Bose
K. Gorden
F. Schneller
Investigational New Drugs, 2017, 35 : 345 - 358
[30] Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study.
Zhou, Caicun
Xiong, Anwen
Li, Wei
Wang, Lei
Wu, Fengying
Yu, Jia
Mao, Chenyu
Qian, Jiong
Zheng, Yulong
Jiang, Haiping
Gao, Yuan
Xiao, Cheng
Wang, Wenxiang
Zhuang, Wu
Yang, Jun
Sun, Jiya
Wang, Hongli
Liu, Ying
Xu, Nong
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 →